MedTrace Logo

Study to Evaluate the Safety of FSR Peptide Versus Placebo Following Punch Biopsy

NCT04473859 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 49

Last updated 2020-07-20

No results posted yet for this study

Summary

The purposes of this study is to test the safety of the study drug (FSR peptide) after a punch biopsy in healthy subjects.

Conditions

  • Wound Heal

Interventions

DRUG

FSR Peptide 20μM

Administered immediately after punch-biopsy and 24 hours after punch biopsy.

DRUG

FSR Peptide 50μM

Administered immediately after punch-biopsy and 24 hours after punch biopsy.

DRUG

FSR Peptide 100μM

Administered immediately after punch-biopsy and 24 hours after punch biopsy.

DRUG

FSR Peptide 200μM

Administered immediately after punch-biopsy and 24 hours after punch biopsy.

DRUG

Placebo

Administered immediately after punch-biopsy and 24 hours after punch biopsy.

Sponsors & Collaborators

  • Xequel Bio, Inc.

    lead OTHER

Principal Investigators

  • Gautam Ghatnekar · CEO

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2008-03-06
Primary Completion
2009-04-28
Completion
2009-04-28
FDA Drug
Yes

Countries

  • Switzerland

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04473859 on ClinicalTrials.gov